Thrombotic Thrombocytopenic Purpura Clinical Trial
Official title:
The ConNeCT Study: Neurological Complications of Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare condition, which has a very high risk of death if not recognised and given immediate treatment. TTP is caused by a very low level of an enzyme in the body, called ADAMTS13. A lack of ADAMTS13 causes multiple small clots to form around the body which can disrupt the blood flow to important organs. Although survival has improved significantly, it is now being recognised that patients with TTP may suffer with longer term complications as a result of their condition; literature from the USA reports higher rates of major depression and also poor memory and reduced concentration in patients with TTP. The investigators aim to improve the understanding of the long-term complications and review, for the first time, forward-looking data at multiple time points in patients with TTP in the UK. Both patients with a new diagnosis and patients with a known diagnosis of TTP identified in NHS hospitals will be included, over a minimum duration of 2 years. This will be a questionnaire based study with both doctor led and participant led questionnaires at pre-determined points in time. By improving the understanding and comparing symptoms to that of the general population, the investigators hope to improve the support and tailor the treatments which can be offered to patients with TTP.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
| Recruiting |
NCT05785468 -
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
|
||
| Completed |
NCT04074187 -
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
|
Phase 2/Phase 3 | |
| Terminated |
NCT00953771 -
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 2 | |
| Recruiting |
NCT01257269 -
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
|
||
| Not yet recruiting |
NCT05568147 -
Aspirin for Prophylaxis of TTP
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05468320 -
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
|
Phase 3 | |
| Completed |
NCT00713193 -
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 3 | |
| Completed |
NCT00426686 -
ADAMTS13 in Thrombotic Thrombocytopenic Purpura
|
N/A | |
| Withdrawn |
NCT00251277 -
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04588194 -
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
|
Phase 2 | |
| Active, not recruiting |
NCT03237819 -
Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care
|
Phase 3 | |
| Completed |
NCT00907751 -
Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
|
Phase 2 | |
| Completed |
NCT03369314 -
Observational Study of the Use of octaplasLG®.
|
||
| Terminated |
NCT01938404 -
Octaplas Adult TTP Trial
|
||
| Completed |
NCT02134171 -
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
|
N/A | |
| Recruiting |
NCT05389007 -
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
|
||
| Withdrawn |
NCT02626663 -
The Role of Microparticles as a Biomarker
|
||
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Terminated |
NCT00593229 -
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
|
N/A |